Tag: LT3001
Novel dual-functional therapy leads to clinical improvements in patients with disabling...
Lumosa Therapeutics has announced positive results from two independent Phase 2 clinical trials of its novel stroke drug LT3001 (odatroltide). LT3001 is described by...
Lumosa, CHI Memorial announce new studies of stroke drug combining clot-busting...
Lumosa Therapeutics, in collaboration with CHI Memorial (Chattanooga, USA), has announced the initiation of multiple Phase 2 clinical trials for LT3001, which the company...
